Embla Medical hf (OSSFF) Stock Price & Analysis
OSSFF Stock Chart & Stats
- Day’s Range
- $3.89 - $4.21
- 52-Week Range
- $3.66 - $6.01
- Previous Close
- $4.04
- Volume
- 10
- Average Volume (3M)
- 0
- Market Cap
- $1.72B
- Enterprise Value
- $14.29B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- $439.43M
- Price to Earnings (P/E)
- 18.2
- Beta
- 0.54
- Next Earnings
- Feb 02, 2027 (Est.)
- EPS Estimate
- 0.07
- Last Dividend Ex-Date
- Mar 13, 2020
- Dividend Yield
- N/A
Embla Medical hf News
OSSFF FAQ
What was Embla Medical hf’s price range in the past 12 months?
What is Embla Medical hf’s market cap?
When is Embla Medical hf’s upcoming earnings report date?
How were Embla Medical hf’s earnings last quarter?
Is Embla Medical hf overvalued?
Does Embla Medical hf pay dividends?
What is Embla Medical hf’s EPS estimate?
How many shares outstanding does Embla Medical hf have?
What happened to Embla Medical hf’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Embla Medical hf?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Embla Medical hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Sveinn Sölvason
- Employees
- 4,500
- Website
- www.emblamedical.com
- Address
- Grjothals 1-5, Reykjavík, SU, 055412, IS
Embla Medical hf (OSSFF) Earnings & Revenues
OSSFF Company Deck
OSSFF Earnings Call
Earnings Call SentimentPositive
The call was generally positive, supported by 10% reported nine-month sales growth, 5% organic growth, strong Prosthetics & Neuro Orthotics performance, stable EBITDA margins, improved profitability in Patient Care, 19% nine-month net profit growth, and a 30% increase in nine-month free cash flow. However, Patient Care sales remained below expectations, U.S. integration efforts constrained growth, competition affected China, gross margin declined year over year in the quarter, and full-year organic growth guidance was narrowed to around 5%. Highlights significantly outweighed the stated challenges.
View all OSSFF earnings summariesOSSFF Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 9 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 4 | 0 | 8 |
